A Phase 2 interventional study of 3 mg Donepezil hydrochloride and 5 mg Donepezil hydrochloride in Dementia With Lewy Bodies (DLB), sponsored by Eisai Co., Ltd.. Completed at 43 sites in Japan. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2013-03-08.
Sponsored by Eisai Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the efficacy and safety of E2020 in patients with Dementia with Lewy Bodies (DLB).
240 studies on the registry are indexed under Lewy Body Disease; 89 are open to participants now.
This study's enrollment of 167 is above the median of 86 across 152 interventional studies indexed under Lewy Body Disease.
Browse Lewy Body Disease studies →Eisai Co., Ltd. is the lead sponsor of 152 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients diagnosed as probable Dementia With Lewy Bodies (DLB) according to the diagnostic criteria for DLB.
Participants having caregivers who submit written consent for cooperative involvement in this study, can routinely stay with participants 3 days a week (at least 4 hours a day), provide participants' information necessary for this study, assist treatment compliance, and escort participants on required visits to study institution.
Exclusion criteria:
Participants with past experience of donepezil (Aricept) therapy at the same study institution.
Participants treated with donepezil in 3 months immediately before starting the observation period.
Participants with a complication of serious neuropsychiatric disease(s) such as stroke, brain tumor, schizophrenia, epilepsia, normal pressure hydrocephalus, mental retardation, brain trauma with unconsciousness, and/or experience of brain surgery causing unsolved deficiency.
Participants with severe complication of cardiovascular, hepatic, renal, hematological, or other diseases unable to secure the safety.
Pregnant or lactating women, or women who are willing to become pregnant no later than 1 month after the scheduled study completion
Participants with severe extrapyramidal disorders (Hoehn \& Yahr staging score is ≥IV)
Participants whose systolic blood pressure is \<90 mmHg or pulse rate is \<50 beats/min.
Participants suspected to have a complication of vascular dementia based upon neurological findings.
Drug: 3 mg Donepezil hydrochloride
Drug: 5 mg Donepezil hydrochloride
Drug: 10 mg Donepezil hydrochloride
Drug: Placebo
Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks. Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily for 12 weeks (Day 1- Day 84) after breakfast.
Also known as: Aricept, Donepezil hydrochloride, E2020
Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks. Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 1- Day 14 (2 weeks). Followed by one 5 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 15- Day 84 (10 weeks).
Also known as: Aricept, Donepezil hydrochloride, E2020
Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks. Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 1- Day 14 (2 weeks). Followed by one 5 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 15- Day 42 (4 weeks). Followed by two 5 mg Donepezil hydrochloride tablets (10 mg) by mouth, once daily after breakfast for Day 43 - Day 84 (6 weeks).
Also known as: Aricept, Donepezil hydrochloride, E2020
Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks. Treatment Period: Two Donepezil hydrochloride Placebo tablets by mouth, once daily for 12 weeks (Day 1- Day 84) after breakfast.
Cognitive Function: Change From Baseline in Mini-mental State Examination (MMSE) Total at Week 12 Last Observation Carried Forward (LOCF)
MMSE measured general cognitive functioning: orientation, memory, attention, calculation, language, visuospatial functions. Total score derived from sub-scores; total ranged from 0 - 30, where a higher score indicated better cognitive state. Change: mean score at Week 12 LOCF minus mean score at baseline. Values at final evaluation were imputed using a Last Observation Carried Forward (LOCF) method.
Time frame: Baseline and every 4 weeks up to 12 weeks
Psychiatric Symptoms: Change From Baseline in Neuropsychiatric Inventory (NPI) Total at Week 12 Last Observation Carried Forward (LOCF)
NPI measured 10 different domains of psychiatric symptoms including delusion and hallucination. Each domain is scored for: present or absent, frequency, and severity. The score derived from sub-scores; total ranged from "0" to "120," higher score indicated "worse neuropsychiatric outcomes." Change: mean score at Week 12 LOCF minus mean score at baseline. Values at final evaluation were imputed using a Last Observation Carried Forward (LOCF) method.
Time frame: Baseline and every 4 weeks up to 12 weeks
Global Clinical Function: Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-plus) Total at Week 12 Last Observation Carried Forward (LOCF)
CIBIC plus is a clinician's interview-based impression of change plus the caregiver's input. It is a seven-point categorical assessment scale for evaluating global clinical function, ranging from "markedly improved" to "markedly worse". Percentage of participants in each category were reported. Values at final evaluation were imputed using a Last Observation Carried Forward (LOCF) method.
Time frame: Baseline and week 12
Burden on Caregiver: Change From Baseline in J-ZBI (Japanese- Zarit Caregiver Burden Interview) Total at Week 12 Last Observation Carried Forward (LOCF)
J-ZBI is a Japanese version instrument to measure and assess the level of burden experienced by the principal caregivers of participants with dementia. ZBI contains 22 items, in which each statement is scored by the caregiver using a 5-point scale. Response options range from 0 (Never) to 4 (Nearly Always). Total score derived from sub-scores; total ranged from 0-88. Higher scores indicate greater burden. Change: mean score at Week 12 LOCF minus mean score at baseline. Values at final evaluation were imputed using a Last Observation Carried Forward (LOCF) method.
Time frame: Baseline and Week 12
| Milestone | 3 mg Donepezil Hydrochloride | 5 mg Donepezil Hydrochloride | 10 mg Donepezil Hydrochloride | Placebo |
|---|---|---|---|---|
| Started | 35 | 33 | 37 | 34 |
| Completed | 31 | 31 | 31 | 30 |
| Not completed | 4 | 2 | 6 | 4 |
| Withdrew: Adverse event | 3 | 1 | 3 | 4 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 2 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 |
MMSE measured general cognitive functioning: orientation, memory, attention, calculation, language, visuospatial functions. Total score derived from sub-scores; total ranged from 0 - 30, where a higher score indicated better cognitive state. Change: mean score at Week 12 LOCF minus mean score at baseline. Values at final evaluation were imputed using a Last Observation Carried Forward (LOCF) method.
| Score on a scale | 3 mg Donepezil Hydrochloride | 5 mg Donepezil Hydrochloride | 10 mg Donepezil Hydrochloride | Placebo |
|---|---|---|---|---|
| Baseline | 20.1 ± 4.2 | 19.7 ± 4.4 | 19.7 ± 4.5 | 18.2 ± 4.8 |
| Change from Baseline (LOCF) | 1.2 ± 3.8 | 3.5 ± 3.2 | 2.3 ± 3.2 | -0.6 ± 2.7 |
NPI measured 10 different domains of psychiatric symptoms including delusion and hallucination. Each domain is scored for: present or absent, frequency, and severity. The score derived from sub-scores; total ranged from "0" to "120," higher score indicated "worse neuropsychiatric outcomes." Change: mean score at Week 12 LOCF minus mean score at baseline. Values at final evaluation were imputed using a Last Observation Carried Forward (LOCF) method.
| Score on a scale | 3 mg Donepezil Hydrochloride | 5 mg Donepezil Hydrochloride | 10 mg Donepezil Hydrochloride | Placebo |
|---|---|---|---|---|
| Baseline | 20.9 ± 13.1 | 14.2 ± 8.4 | 19.1 ± 11.8 | 18.4 ± 8.9 |
| Change from Baseline (LOCF) | -4.3 ± 21.5 | -5.9 ± 6.5 | -10.2 ± 12.0 | -3.1 ± 10.9 |
CIBIC plus is a clinician's interview-based impression of change plus the caregiver's input. It is a seven-point categorical assessment scale for evaluating global clinical function, ranging from "markedly improved" to "markedly worse". Percentage of participants in each category were reported. Values at final evaluation were imputed using a Last Observation Carried Forward (LOCF) method.
| Percentage of Participants | 3 mg Donepezil Hydrochloride | 5 mg Donepezil Hydrochloride | 10 mg Donepezil Hydrochloride | Placebo |
|---|---|---|---|---|
| Marked improvement | 3.6 | 17.9 | 3.8 | 0 |
| Moderate Improvement | 17.9 | 17.9 | 11.5 | 3.7 |
| Minimal Improvement | 50.0 | 35.7 | 50.0 | 29.6 |
| No Change | 21.4 | 14.3 | 30.8 | 18.5 |
| Minimal Worsening | 3.6 | 7.1 | 3.8 | 37.0 |
| Moderate Worsening | 0 | 7.1 | 0 | 11.1 |
| Marked Worsening | 3.6 | 0 | 0 | 0 |
J-ZBI is a Japanese version instrument to measure and assess the level of burden experienced by the principal caregivers of participants with dementia. ZBI contains 22 items, in which each statement is scored by the caregiver using a 5-point scale. Response options range from 0 (Never) to 4 (Nearly Always). Total score derived from sub-scores; total ranged from 0-88. Higher scores indicate greater burden. Change: mean score at Week 12 LOCF minus mean score at baseline. Values at final evaluation were imputed using a Last Observation Carried Forward (LOCF) method.
| Score on a scale | 3 mg Donepezil Hydrochloride | 5 mg Donepezil Hydrochloride | 10 mg Donepezil Hydrochloride | Placebo |
|---|---|---|---|---|
| Baseline | 28.3 ± 14.4 | 23.2 ± 11.6 | 26.9 ± 16.3 | 22.3 ± 9.8 |
| Change from Baseline (LOCF) | -1.3 ± 11.1 | -0.6 ± 16.4 | -5.2 ± 13.8 | 2.9 ± 9.1 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 3 mg Donepezil Hydrochloride | — | 2/35 (5.7%) | 24/35 (68.6%) |
| 5 mg Donepezil Hydrochloride | — | 2/33 (6.1%) | 27/33 (81.8%) |
| 10 mg Donepezil Hydrochloride | — | 4/37 (10.8%) | 32/37 (86.5%) |
| Placebo | — | 2/34 (5.9%) | 24/34 (70.6%) |
| Event | 3 mg Donepezil Hydrochloride | 5 mg Donepezil Hydrochloride | 10 mg Donepezil Hydrochloride | Placebo |
|---|---|---|---|---|
| ParaparesisNervous system disorders | 0/35 | 1/33 | 0/37 | 0/34 |
| Inguinal HerniaGastrointestinal disorders | 0/35 | 1/33 | 0/37 | 0/34 |
| RestlessnessPsychiatric disorders | 0/35 | 0/33 | 0/37 | 1/34 |
| Diabetic NeuropathyNervous system disorders | 0/35 | 0/33 | 0/37 | 1/34 |
| Pelvic FractureInjury, poisoning and procedural complications | 0/35 | 0/33 | 0/37 | 1/34 |
| HallucinationPsychiatric disorders | 1/35 | 0/33 | 1/37 | 0/34 |
| Cerebral InfarctionNervous system disorders | 1/35 | 0/33 | 0/37 | 0/34 |
| Subarachnoid HaemorrhageNervous system disorders | 1/35 | 0/33 | 0/37 | 0/34 |
| PyelonephritisInfections and infestations | 0/35 | 0/33 | 1/37 | 0/34 |
| Back PainMusculoskeletal and connective tissue disorders | 0/35 | 0/33 | 1/37 | 0/34 |
| Event | 3 mg Donepezil Hydrochloride | 5 mg Donepezil Hydrochloride | 10 mg Donepezil Hydrochloride | Placebo |
|---|---|---|---|---|
| Blood Creatine Phosphokinase IncreasedInvestigations | 5/35 | 3/33 | 5/37 | 2/34 |
| Blood Pressure IncreasedInvestigations | 5/35 | 2/33 | 2/37 | 1/34 |
| DiarrhoeaGastrointestinal disorders | 0/35 | 4/33 | 3/37 | 4/34 |
| NasopharyngitisInfections and infestations | 3/35 | 2/33 | 4/37 | 1/34 |
| Blood Urine PresentInvestigations | 0/35 | 2/33 | 4/37 | 3/34 |
| White Blood Cell Count DecreasedInvestigations | 0/35 | 0/33 | 4/37 | 1/34 |
| ConstipationGastrointestinal disorders | 0/35 | 3/33 | 1/37 | 1/34 |
| Back PainMusculoskeletal and connective tissue disorders | 2/35 | 1/33 | 2/37 | 3/34 |
| Blood Triglycerides IncreasedInvestigations | 2/35 | 1/33 | 0/37 | 3/34 |
| Blood Alkaline Phosphatase IncreasedInvestigations | 0/35 | 0/33 | 1/37 | 3/34 |
| Age Continuous(years) | 3 mg Donepezil Hydrochloride | 5 mg Donepezil Hydrochloride | 10 mg Donepezil Hydrochloride | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 79.6 ± 4.5 | 77.9 ± 6.7 | 78.4 ± 6.1 | 78.7 ± 4.9 | 78.7 ± 5.6 |
| Sex: Female, Male(Participants) | 3 mg Donepezil Hydrochloride | 5 mg Donepezil Hydrochloride | 10 mg Donepezil Hydrochloride | Placebo | Total |
|---|---|---|---|---|---|
| Female | 18 | 16 | 33 | 23 | 90 |
| Male | 17 | 17 | 4 | 11 | 49 |
The record gives a start of Nov 2007, a primary completion of Feb 2010 and a completion of Feb 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2013, 3 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Donepezil